Skip to main content

Market Overview

Johnson & Johnson COVID-19 Vaccine Approval Could Be Near But The Company Is Low On Supply

Johnson & Johnson COVID-19 Vaccine Approval Could Be Near But The Company Is Low On Supply

Johnson & Johnson (NYSE: JNJ) only has a few million doses of its COVID-19 vaccine in its inventory even though regulatory authorization could just be weeks away, Reuters reported Wednesday.

What Happened: The revelation regarding the vaccine stock was made by Jeffrey Zients, the Biden administration’s COVID-19 response coordinator, according to Reuters. 

The New Jersey-based drug multinational is reportedly committed to providing 100 million doses by June but deliveries are likely to be “back-end loaded,” as per Zients.

See also: How to Buy Johnson & Johnson Stock

“Across the last few weeks we’ve learned that there is not a big inventory of Johnson and Johnson. There’s a few million doses that we’ll start with,” said Zients.

Why It Matters: The Food and Drug Administration has scheduled a meeting of the Vaccines and Related Biological Products Advisory Committee on Feb. 26 to discuss the COVID-19 vaccine made by Johnson & Johnson subsidiary Janssen Biotech Inc.

The Janssen vaccine can be administered in a single dose unlike vaccines made by Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), both of which have already received emergency approval

Janssen’s shot also eliminates the need for ultracold storage, which is required for the other two approved vaccines.

The United States faces a vaccine crunch as both Pfizer and Moderna have promised to deliver 200 million doses by the end of March, but fewer than 72 million doses have been shipped and 55 million doses administered, noted Reuters.

Price Action: Johnson and Johnson shares closed nearly 0.4% higher at $165.66 on Wednesday and gained 0.13% in the after-hours session.


Related Articles (JNJ)

View Comments and Join the Discussion!

Posted-In: Covid-19 vaccines ReutersBiotech News FDA General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at